行情

VTGN

VTGN

VistaGen
NASDAQ

实时行情|Nasdaq Last Sale

0.2960
-0.0040
-1.33%
盘后: 0.3050 +0.009 +3.04% 16:17 11/15 EST
开盘
0.3198
昨收
0.3000
最高
0.3198
最低
0.2943
成交量
158.35万
成交额
--
52周最高
1.920
52周最低
0.2943
市值
1,279.40万
市盈率(TTM)
-0.4218
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VTGN 新闻

  • 收盘:美股再创新高 道指首次跨越28000点里程碑
  • 新浪美股.3小时前
  • 周五美油期货收高1.7% 布油上涨1.6%
  • 新浪美股.3小时前
  • 分析师:某位投资大佬可能正在“嗅探”Netflix
  • 新浪财经.3小时前
  • FAA局长:737 MAX机型获复飞批准"不受时间表指引"
  • 新浪美股.4小时前

更多

所属板块

制药
+1.25%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

VTGN 简况

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
展开

Webull提供Vistagen Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。